mechanism of action of bitopertin to treat patients with epp
Published 1 year ago • 207 plays • Length 1:45Download video MP4
Download video MP3
Similar videos
-
3:17
results from a murine model investigating bitopertin for the treatment of epp
-
2:50
beacon trial results: safety & efficacy of bitopertin in adults with epp
-
1:39
the mechanism of action of navtemadlin and its role in mf
-
1:06
mechanism of action of mitapivat and its potential in the treatment of scd
-
0:52
the role and clinical use of tpo receptor agonists in the treatment of itp
-
3:35
epigenomics in precision oncology
-
12:33
3mensio ct pre-case planning: valve-in-valve tavr in epic/biocor
-
1:06:04
itp: novel treatments
-
0:50
the etiology of erythropoietic protoporphyria
-
3:26
the risk of thrombotic events in patients with mgus: an analysis from the istopmm trial
-
3:17
thrombopoietin receptor agonists in itp: current status and future outlooks
-
1:16
using rwd to evaluate the use of fedratinib as a potential bridge to hsct in patients with mf
-
4:24
investigating production failure and out-of-specification production of car t-cell therapeutics
-
2:51
ruxolitinib in combination with abemaciclib for patients with primary or post-pv/et myelofibrosis
-
1:32
factors contributing to the pathogenesis of icaht
-
0:52
rilzabrutinib: a novel promising btk inhibitor being explored in itp
-
1:54
fostamatinib and efgartigimod: novel agents in the treatment of itp
-
1:28
phase i study of pevonedistat and ibrutinib in r/r b-nhl
-
1:46
updated analyses from the pathfinder trial: avapritinib therapy in advanced systemic mastocytosis
-
2:41
an overview of the latest advances in hematology
-
2:04
mechanism of action of evorpacept
-
2:13
splicing mutations in post-et/post-pv myelofibrosis